Richard D. Truesdell, Jr.

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by NovoCure Limited of $575 million aggregate principal amount of its 0.000%…

Davis Polk advised the representatives of the underwriters in connection with the $345 million initial public offering of 14,375,000 shares of common stock of Atea Pharmaceuticals, Inc.,…

Davis Polk advised the joint book-running managers and representatives of the several underwriters on the $72 million initial public offering by Biodesix, Inc. The common stock is listed on…

Davis Polk advised Gatos Silver, Inc. on its SEC-registered initial public offering of 21,430,000 common shares for total gross proceeds of approximately $150 million. In addition, Gatos…

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…

Davis Polk is advising Morgan Stanley & Co. LLC as lead financial adviser and sole placement agent to RMG Acquisition Corp. (“RMG”), a special purpose acquisition company, in connection…

  Davis Polk advised the representatives of the several underwriters in connection with the $96 million initial public offering by Mission Produce, Inc. of 8,000,000 shares of its…

Davis Polk advised Gilead Sciences, Inc. in connection with an SEC-registered offering of $7.25 billion aggregate principal amount of senior notes, consisting of (i) $500 million aggregate…

Davis Polk advised MDLIVE Inc. in connection with its private placement of approximately $50 million in shares of its Series F preferred stock.MDLIVE offers virtual healthcare services to…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Valero Energy Corporation of $2.5 billion aggregate principal amount of its floating-rate senior notes…